Galapagos Awarded Grant to Accelerate Drug Discovery
Date Posted: Wednesday, February 11, 2009
Galapagos NV has announced that it has been awarded a €837,000 grant from the Flanders government through the Institute for the Promotion of Innovation by Science and Technology (IWT). Galapagos will elucidate the structure of novel drug targets and related small molecules in its bone & joint disease portfolio.
The two-year project "Drug discovery for bone and joint protection: structural biology for novel targets and their inhibitors" focuses on Galapagos' novel drug targets and the candidate drugs that bind to these targets. This information will help Galapagos to design potent and selective drugs and thus potentially improve their efficacy to treat bone and joint diseases. Galapagos will collaborate on this project with the renowned Structural Biology Brussels group at the Flanders Institute for Biotechnology (VIB).
"This grant gives us an opportunity to collaborate with the VIB's top structural biology group, thereby adding to our drug discovery capabilities," said Graham Dixon, SVP Drug Discovery for Galapagos.
"Through this research we aim to progress our understanding of these novel drug targets and accelerate the development of candidate drugs for bone & joint diseases."
Further Information: http://www.glpg.com
Related news from our archive
OctoPlus Signs Service Contract with Galapagos
OctoPlus to manufacture clinical trial material for Galapagos' Phase II study of Nanocort®, a liposome formulation of prednisolone.
Galapagos Reveals Key Drug Target for Alzheimer's Disease
The data presented in Science article describes how GPR3 was identified in human cells using Galapagos' platform.
Galapagos and GlaxoSmithKline Expand Anti-infectives Alliance
Galapagos announced that it has expanded the alliance in antibacterials and antivirals with GlaxoSmithKline (GSK) to include three more discovery targets.
Galapagos Enters Strategic Alliance in Diabetes and Obesity with Merck & Co.
Galapagos to discover small molecule candidate drugs for pre-clinical development based on novel Galapagos targets.
Galapagos Selects Pre-Clinical Candidate Drug for Cachexia
Galapagos’ pre-clinical candidate G100192 has demonstrated successful Proof of Concept in animal studies.
Galapagos Delivers Pre-Clinical Candidate Drug in Alliance with GlaxoSmithKline
Galapagos has reached milestones on other compounds in the alliance, triggering payments totaling €7.6 million to Galapagos.
Galapagos and GlaxoSmithKline Expand Osteoarthritis Alliance
Galapagos receives a payment of €2 million cash from GSK for the addition of two new drug targets.
Galapagos Extends Drug Discovery Collaboration with Amgen into 2010
BioFocus DPI will continue to provide biology, computational and medicinal chemistry services and will supply small molecule compounds for use in Amgen's discovery programs.